Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot

  • As Bavarian Nordic A/S BVNRY was in the headlines recently due to the smallpox vaccine amid rising cases of monkeypox, the company is also getting ready to evaluate its COVID-19 booster, ABNCoV2, in a pivotal study.
  • ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus-like particle technology. 
  • The upcoming Phase 3 trial will include Pfizer Inc PFEBioNTech SE's BNTX COVID-19 shot in the comparator arm.
  • Also Read: EU, Bavarian Nordic Ink Supply Pact For 110,000 Monkeypox Vaccines.
  • The company has chosen Comirnaty to potentially support the study's primary objective and demonstrate that the neutralizing antibodies induced by ABNCoV2 are non-inferior to the licensed mRNA-based vaccine. 
  • The Phase 3 trial will enroll approximately 4,000 participants who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. 
  • The trial consists of two groups, which will run in parallel. The active, controlled group will enroll 1,000 subjects who will be randomized to receive either a single 100 µg dose of ABNCoV2 or a single 30 µg adult booster dose of Comirnaty. 
  • The other group will evaluate the safety and tolerability of the vaccine in 3,000 subjects who will receive a single 100 µg dose of ABNCoV2.
  • The Phase 3 trial will start enrolling in August 2022. The company anticipates the initial data read-out before the end of 2022, which will allow for a rolling submission to the regulatory authorities, aiming to obtain approval of the vaccine in 2023.

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechLarge CapNewsHealth CareSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.